Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease

P. Szabolcs, M. Reese, K. B. Yancey, R. P. Hall, J. Kurtzberg

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

In this case report we describe a novel treatment with two chimeric monoclonal antibodies (MoAb) targeting the autoimmune B cell clone responsible for bullous pemphigoid (BP) as a manifestation of steroid refractory chronic graft-versus-host disease (GVHD) that developed after unrelated cord blood transplantation. Monitoring the BP-specific circulating antibodies and CD25-expressing activated T lymphocyte subset led us to combine anti-CD20 (Rituximab) mediated B cell ablation with anti-CD25 (Daclizumab) therapy to block CD4+ T cell help. Complete clinical and serologic response was achieved within 4 weeks of initiation of therapy allowing global immunosuppression to be dramatically reduced.

Original languageEnglish (US)
Pages (from-to)327-329
Number of pages3
JournalBone Marrow Transplantation
Volume30
Issue number5
DOIs
StatePublished - Sep 2002

Fingerprint

Bullous Pemphigoid
Graft vs Host Disease
Anti-Idiotypic Antibodies
B-Lymphocytes
T-Lymphocyte Subsets
Fetal Blood
Immunosuppression
Therapeutics
Clone Cells
Transplantation
Steroids
Monoclonal Antibodies
T-Lymphocytes
Antibodies

Keywords

  • Bullous pemphigoid
  • Daclizumab
  • GVHD
  • Rituximab
  • Transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease. / Szabolcs, P.; Reese, M.; Yancey, K. B.; Hall, R. P.; Kurtzberg, J.

In: Bone Marrow Transplantation, Vol. 30, No. 5, 09.2002, p. 327-329.

Research output: Contribution to journalArticle

@article{dadeaf6386874fe1babe0c3d129a4e0f,
title = "Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease",
abstract = "In this case report we describe a novel treatment with two chimeric monoclonal antibodies (MoAb) targeting the autoimmune B cell clone responsible for bullous pemphigoid (BP) as a manifestation of steroid refractory chronic graft-versus-host disease (GVHD) that developed after unrelated cord blood transplantation. Monitoring the BP-specific circulating antibodies and CD25-expressing activated T lymphocyte subset led us to combine anti-CD20 (Rituximab) mediated B cell ablation with anti-CD25 (Daclizumab) therapy to block CD4+ T cell help. Complete clinical and serologic response was achieved within 4 weeks of initiation of therapy allowing global immunosuppression to be dramatically reduced.",
keywords = "Bullous pemphigoid, Daclizumab, GVHD, Rituximab, Transplantation",
author = "P. Szabolcs and M. Reese and Yancey, {K. B.} and Hall, {R. P.} and J. Kurtzberg",
year = "2002",
month = "9",
doi = "10.1038/sj.bmt.1703654",
language = "English (US)",
volume = "30",
pages = "327--329",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease

AU - Szabolcs, P.

AU - Reese, M.

AU - Yancey, K. B.

AU - Hall, R. P.

AU - Kurtzberg, J.

PY - 2002/9

Y1 - 2002/9

N2 - In this case report we describe a novel treatment with two chimeric monoclonal antibodies (MoAb) targeting the autoimmune B cell clone responsible for bullous pemphigoid (BP) as a manifestation of steroid refractory chronic graft-versus-host disease (GVHD) that developed after unrelated cord blood transplantation. Monitoring the BP-specific circulating antibodies and CD25-expressing activated T lymphocyte subset led us to combine anti-CD20 (Rituximab) mediated B cell ablation with anti-CD25 (Daclizumab) therapy to block CD4+ T cell help. Complete clinical and serologic response was achieved within 4 weeks of initiation of therapy allowing global immunosuppression to be dramatically reduced.

AB - In this case report we describe a novel treatment with two chimeric monoclonal antibodies (MoAb) targeting the autoimmune B cell clone responsible for bullous pemphigoid (BP) as a manifestation of steroid refractory chronic graft-versus-host disease (GVHD) that developed after unrelated cord blood transplantation. Monitoring the BP-specific circulating antibodies and CD25-expressing activated T lymphocyte subset led us to combine anti-CD20 (Rituximab) mediated B cell ablation with anti-CD25 (Daclizumab) therapy to block CD4+ T cell help. Complete clinical and serologic response was achieved within 4 weeks of initiation of therapy allowing global immunosuppression to be dramatically reduced.

KW - Bullous pemphigoid

KW - Daclizumab

KW - GVHD

KW - Rituximab

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=0036739404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036739404&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1703654

DO - 10.1038/sj.bmt.1703654

M3 - Article

C2 - 12209356

AN - SCOPUS:0036739404

VL - 30

SP - 327

EP - 329

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 5

ER -